메뉴 건너뛰기




Volumn 50, Issue 1, 2015, Pages 40-44

Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: A multi-center analysis

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE;

EID: 84920666375     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.201     Document Type: Article
Times cited : (12)

References (22)
  • 1
    • 0032487923 scopus 로고    scopus 로고
    • Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
    • Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341-1348.
    • (1998) N Engl J Med , vol.339 , pp. 1341-1348
    • Soignet, S.L.1    Maslak, P.2    Wang, Z.G.3    Jhanwar, S.4    Calleja, E.5    Dardashti, L.J.6
  • 2
    • 42449128875 scopus 로고    scopus 로고
    • Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002
    • Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control 2008; 19: 379-390.
    • (2008) Cancer Causes Control , vol.19 , pp. 379-390
    • Yamamoto, J.F.1    Goodman, M.T.2
  • 3
    • 61949441174 scopus 로고    scopus 로고
    • Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet
    • Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113: 1875-1891.
    • (2009) Blood , vol.113 , pp. 1875-1891
    • Sanz, M.A.1    Grimwade, D.2    Tallman, M.S.3    Lowenberg, B.4    Fenaux, P.5    Estey, E.H.6
  • 4
    • 10744220024 scopus 로고    scopus 로고
    • Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: A multicenter study by the PETHEMA Group
    • Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, Rivas C et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA Group. Blood 2004; 103: 1237-1243.
    • (2004) Blood , vol.103 , pp. 1237-1243
    • Sanz, M.A.1    Martin, G.2    Gonzalez, M.3    Leon, A.4    Rayon, C.5    Rivas, C.6
  • 5
    • 0033566639 scopus 로고    scopus 로고
    • A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia: The European APL Group
    • Fenauz P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia: The European APL Group. Blood 1999; 94: 1192-1200.
    • (1999) Blood , vol.94 , pp. 1192-1200
    • Fenauz, P.1    Chastang, C.2    Chevret, S.3    Sanz, M.4    Dombret, H.5    Archimbaud, E.6
  • 6
    • 77958499078 scopus 로고    scopus 로고
    • Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by riskadapted consolidation for adults younger than 61 years: Results of the AIDA-2000 trial of the GIMEMA group
    • Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by riskadapted consolidation for adults younger than 61 years: Results of the AIDA-2000 trial of the GIMEMA group. Blood 2010; 116: 3171-3179.
    • (2010) Blood , vol.116 , pp. 3171-3179
    • Lo-Coco, F.1    Avvisati, G.2    Vignetti, M.3    Thiede, C.4    Orlando, S.M.5    Iacobelli, S.6
  • 7
    • 0037115195 scopus 로고    scopus 로고
    • All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol
    • Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002; 100: 4298-4302.
    • (2002) Blood , vol.100 , pp. 4298-4302
    • Tallman, M.S.1    Andersen, J.W.2    Schiffer, C.A.3    Appelbaum, F.R.4    Feusner, J.H.5    Woods, W.G.6
  • 8
    • 84879409297 scopus 로고    scopus 로고
    • Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients
    • Adès L, Chevret S, Raffoux E, Guerci-Bresler A, Pigneux A, Vey N et al. Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients. Am J Hematol 2013; 88: 556-559.
    • (2013) Am J Hematol , vol.88 , pp. 556-559
    • Adès, L.1    Chevret, S.2    Raffoux, E.3    Guerci-Bresler, A.4    Pigneux, A.5    Vey, N.6
  • 9
    • 0034663162 scopus 로고    scopus 로고
    • Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups
    • Sanz MA, Lo Coco F, Martín G, Avvisati G, Rayon C, Barbui T et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-1253.
    • (2000) Blood , vol.96 , pp. 1247-1253
    • Sanz, M.A.1    Lo Coco, F.2    Martín, G.3    Avvisati, G.4    Rayon, C.5    Barbui, T.6
  • 10
    • 0030610687 scopus 로고    scopus 로고
    • Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
    • Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qui QY et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360.
    • (1997) Blood , vol.89 , pp. 3354-3360
    • Shen, Z.X.1    Chen, G.Q.2    Ni, J.H.3    Li, X.S.4    Xiong, S.M.5    Qui, Q.Y.6
  • 12
    • 0032417947 scopus 로고    scopus 로고
    • Role of autologous bone marrow transplantation as consolidation therapy in acute promyelocytic leukemia patients in complete remission
    • Ottaviani E, Martinelli G, Testoni N, Visani G, Tani M, Tura S. Role of autologous bone marrow transplantation as consolidation therapy in acute promyelocytic leukemia patients in complete remission. Haematologica 1998; 83: 1051-1055.
    • (1998) Haematologica , vol.83 , pp. 1051-1055
    • Ottaviani, E.1    Martinelli, G.2    Testoni, N.3    Visani, G.4    Tani, M.5    Tura, S.6
  • 13
    • 0027954036 scopus 로고
    • European survey of bone marrow transplantation in acute promyelocytic leukemia (M3). Working Party on Acute Leukemia of the European Cooperative Group for Bone Marrow Transplantation (EMBT)
    • Mandelli F, Labopin M, Granena A, Irionda A, Prentice G, Bacigalupo A et al. European survey of bone marrow transplantation in acute promyelocytic leukemia (M3). Working Party on Acute Leukemia of the European Cooperative Group for Bone Marrow Transplantation (EMBT). Bone Marrow Transplant 1994; 14: 293-298.
    • (1994) Bone Marrow Transplant , vol.14 , pp. 293-298
    • Mandelli, F.1    Labopin, M.2    Granena, A.3    Irionda, A.4    Prentice, G.5    Bacigalupo, A.6
  • 14
    • 16644373167 scopus 로고    scopus 로고
    • Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: A retrospective analysis of the European acute promyelocytic leukemia group
    • de Botton S, Fawaz A, Chevret S, Dombret H, Thomas X, Sanz M et al. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol 2005; 23: 120-126.
    • (2005) J Clin Oncol , vol.23 , pp. 120-126
    • De Botton, S.1    Fawaz, A.2    Chevret, S.3    Dombret, H.4    Thomas, X.5    Sanz, M.6
  • 16
    • 60049099401 scopus 로고    scopus 로고
    • Delayed hematological recovery following autologous transplantation utilizing peripheral blood stem cells harvested after treatment with arsenic trioxide
    • Ueki T, Ohashi K, Jinta M, Okuyama Y, Hiruma K, Akiyama H et al. Delayed hematological recovery following autologous transplantation utilizing peripheral blood stem cells harvested after treatment with arsenic trioxide. Pathol Oncol Res 2008; 14: 387-390.
    • (2008) Pathol Oncol Res , vol.14 , pp. 387-390
    • Ueki, T.1    Ohashi, K.2    Jinta, M.3    Okuyama, Y.4    Hiruma, K.5    Akiyama, H.6
  • 17
    • 84879164951 scopus 로고    scopus 로고
    • Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia
    • Yanada M, Tsuzuki M, Fujita H, Fujimaki K, Fujisawa S, Sunami K et al. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood 2013; 121: 3095-3102.
    • (2013) Blood , vol.121 , pp. 3095-3102
    • Yanada, M.1    Tsuzuki, M.2    Fujita, H.3    Fujimaki, K.4    Fujisawa, S.5    Sunami, K.6
  • 18
    • 0010740572 scopus 로고    scopus 로고
    • In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins
    • Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88: 1052-1061.
    • (1996) Blood , vol.88 , pp. 1052-1061
    • Chen, G.Q.1    Zhu, J.2    Shi, X.G.3    Ni, J.H.4    Zhong, H.J.5    Si, G.Y.6
  • 19
    • 3242666928 scopus 로고    scopus 로고
    • The potential of arsenic trioxide in the treatment of malignant disease: Past, present, and future
    • Evens AM, Tallman MS, Gartenhaus RB. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res 2004; 28: 891-900.
    • (2004) Leuk Res , vol.28 , pp. 891-900
    • Evens, A.M.1    Tallman, M.S.2    Gartenhaus, R.B.3
  • 20
    • 0033568238 scopus 로고    scopus 로고
    • Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway
    • Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94: 2102-2111.
    • (1999) Blood , vol.94 , pp. 2102-2111
    • Jing, Y.1    Dai, J.2    Chalmers-Redman, R.M.3    Tatton, W.G.4    Waxman, S.5
  • 21
  • 22
    • 0034663032 scopus 로고    scopus 로고
    • Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis
    • Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell RP et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000; 96: 1525-1530.
    • (2000) Blood , vol.96 , pp. 1525-1530
    • Roboz, G.J.1    Dias, S.2    Lam, G.3    Lane, W.J.4    Soignet, S.L.5    Warrell, R.P.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.